Nova Biomedical integrates PAIA Titer assay technology into cell line development
What happened
Nova Biomedical integrated PAIA Titer assay technology into its cell line development portfolio, enabling the use of VIPS® PRO and Cell Metric® X platforms to assess product quality and productivity earlier in the process. John Luck, president of Nova Biomedical's Biopharma business, noted that this integration allows scientists to identify high-potential clones sooner.
From selectscience.net
Why it matters
The technology complements Nova Biomedical's existing capabilities, including titer, cell counting, and glycan analysis. By bringing productivity and quality data forward in the workflow, the integration supports making earlier and more informed decisions regarding which clones to advance.
From selectscience.net
Who's involved
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- BioPharmaSpeculative
The BioPharma business unit might reduce resource costs by identifying high-potential clones earlier in the cell line development process.